vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and RMR GROUP INC. (RMR). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $66.7M, roughly 1.3× RMR GROUP INC.). On growth, RMR GROUP INC. posted the faster year-over-year revenue change (40.8% vs 17.7%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
RMR Group Inc. is a U.S.-headquartered alternative asset management firm specializing in real estate and real estate-related investments. It operates across commercial property, residential real estate, and infrastructure segments, serving institutional investors, high-net-worth individuals, and retail clients across key global markets.
IOVA vs RMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $66.7M |
| Net Profit | — | $12.2M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | 48.1% |
| Net Margin | — | 18.3% |
| Revenue YoY | 17.7% | 40.8% |
| Net Profit YoY | — | 91.1% |
| EPS (diluted) | — | $0.71 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $66.7M | ||
| Q3 25 | $67.5M | — | ||
| Q2 25 | $60.0M | — | ||
| Q1 25 | $49.3M | — | ||
| Q4 24 | $73.7M | — | ||
| Q3 24 | $58.6M | — | ||
| Q2 24 | $31.1M | — | ||
| Q1 24 | $715.0K | — |
| Q4 25 | — | $12.2M | ||
| Q3 25 | $-91.3M | — | ||
| Q2 25 | $-111.7M | — | ||
| Q1 25 | $-116.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | — | ||
| Q2 24 | $-97.1M | — | ||
| Q1 24 | $-113.0M | — |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | 48.1% | ||
| Q3 25 | -140.7% | — | ||
| Q2 25 | -189.8% | — | ||
| Q1 25 | -245.8% | — | ||
| Q4 24 | -117.5% | — | ||
| Q3 24 | -152.1% | — | ||
| Q2 24 | -327.6% | — | ||
| Q1 24 | -16464.6% | — |
| Q4 25 | — | 18.3% | ||
| Q3 25 | -135.3% | — | ||
| Q2 25 | -186.2% | — | ||
| Q1 25 | -235.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | — | ||
| Q2 24 | -312.2% | — | ||
| Q1 24 | -15800.8% | — |
| Q4 25 | — | $0.71 | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $-0.28 | — | ||
| Q2 24 | $-0.34 | — | ||
| Q1 24 | $-0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $49.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $232.7M |
| Total Assets | $913.2M | $687.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $49.3M | ||
| Q3 25 | $300.8M | — | ||
| Q2 25 | $301.2M | — | ||
| Q1 25 | $359.7M | — | ||
| Q4 24 | $323.8M | — | ||
| Q3 24 | $397.5M | — | ||
| Q2 24 | $412.5M | — | ||
| Q1 24 | $356.2M | — |
| Q4 25 | $698.6M | $232.7M | ||
| Q3 25 | $702.3M | — | ||
| Q2 25 | $698.5M | — | ||
| Q1 25 | $767.9M | — | ||
| Q4 24 | $710.4M | — | ||
| Q3 24 | $773.5M | — | ||
| Q2 24 | $768.5M | — | ||
| Q1 24 | $680.0M | — |
| Q4 25 | $913.2M | $687.1M | ||
| Q3 25 | $904.9M | — | ||
| Q2 25 | $907.4M | — | ||
| Q1 25 | $966.7M | — | ||
| Q4 24 | $910.4M | — | ||
| Q3 24 | $991.1M | — | ||
| Q2 24 | $964.3M | — | ||
| Q1 24 | $869.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $10.7M |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | 0.88× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $10.7M | ||
| Q3 25 | $-78.7M | — | ||
| Q2 25 | $-67.4M | — | ||
| Q1 25 | $-103.7M | — | ||
| Q4 24 | $-73.3M | — | ||
| Q3 24 | $-59.0M | — | ||
| Q2 24 | $-98.4M | — | ||
| Q1 24 | $-122.3M | — |
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-89.5M | — | ||
| Q2 25 | $-74.9M | — | ||
| Q1 25 | $-109.9M | — | ||
| Q4 24 | $-77.5M | — | ||
| Q3 24 | $-61.3M | — | ||
| Q2 24 | $-98.9M | — | ||
| Q1 24 | $-126.5M | — |
| Q4 25 | -71.3% | — | ||
| Q3 25 | -132.7% | — | ||
| Q2 25 | -124.9% | — | ||
| Q1 25 | -222.8% | — | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -104.6% | — | ||
| Q2 24 | -317.9% | — | ||
| Q1 24 | -17685.3% | — |
| Q4 25 | 10.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 583.4% | — |
| Q4 25 | — | 0.88× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
RMR
| Management Service Incentive | $23.6M | 35% |
| Industrial Logistics Properties Trust | $15.1M | 23% |
| Managed Private Real Estate Capital | $11.1M | 17% |
| Office Properties Income Trust | $5.6M | 8% |
| Other Private Entities | $5.3M | 8% |
| RMR Residential | $3.4M | 5% |
| Sonesta International Hotels Corporation | $2.1M | 3% |
| Investment Advisory Management And Administrative Service | $1.2M | 2% |
